234 related articles for article (PubMed ID: 30429020)
21. Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis.
Parra-Medina R; Castañeda-González JP; Chaves-Cabezas V; Alzate JP; Chaves JJ
Pathol Res Pract; 2024 May; 257():155276. PubMed ID: 38603842
[TBL] [Abstract][Full Text] [Related]
22. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.
Singhi AD; Krasinskas AM; Choudry HA; Bartlett DL; Pingpank JF; Zeh HJ; Luvison A; Fuhrer K; Bahary N; Seethala RR; Dacic S
Mod Pathol; 2016 Jan; 29(1):14-24. PubMed ID: 26493618
[TBL] [Abstract][Full Text] [Related]
23. The significance of BAP1 and MTAP/CDKN2A expression in well-differentiated papillary mesothelial tumour: a series of 21 cases and a review of the literature.
Hassan A; Prabhakaran S; Pulford E; Hocking AJ; Godbolt D; Ziad F; Pandita A; Wessels A; Hussey M; Russell PA; Klebe S
Pathology; 2024 May; ():. PubMed ID: 38789301
[TBL] [Abstract][Full Text] [Related]
24. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
Hida T; Matsumoto S; Hamasaki M; Kawahara K; Tsujimura T; Hiroshima K; Kamei T; Taguchi K; Iwasaki A; Oda Y; Honda H; Nabeshima K
Cancer Sci; 2015 Nov; 106(11):1635-41. PubMed ID: 26291840
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review.
Linton A; Kao S; Vardy J; Clarke S; van Zandwijk N; Klebe S
Asia Pac J Clin Oncol; 2013 Sep; 9(3):273-9. PubMed ID: 23167246
[TBL] [Abstract][Full Text] [Related]
26. Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
Churg A; Nabeshima K; Ali G; Bruno R; Fernandez-Cuesta L; Galateau-Salle F
Lung Cancer; 2018 Oct; 124():95-101. PubMed ID: 30268487
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
Rusch A; Ziltener G; Nackaerts K; Weder W; Stahel RA; Felley-Bosco E
Lung Cancer; 2015 Jan; 87(1):77-9. PubMed ID: 25468148
[TBL] [Abstract][Full Text] [Related]
28. Pathological and molecular biological approaches to early mesothelioma.
Tsujimura T; Torii I; Sato A; Song M; Fukuoka K; Hasegawa S; Nakano T
Int J Clin Oncol; 2012 Feb; 17(1):40-7. PubMed ID: 22237727
[TBL] [Abstract][Full Text] [Related]
29. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
Husain AN; Mirza MK; Gibbs A; Hiroshima K; Chi Y; Boumendjel R; Stang N; Krausz T; Galateau-Salle F
Lung Cancer; 2014 Mar; 83(3):324-8. PubMed ID: 24440278
[TBL] [Abstract][Full Text] [Related]
30. Loss of expression of BAP1 predicts longer survival in mesothelioma.
Farzin M; Toon CW; Clarkson A; Sioson L; Watson N; Andrici J; Gill AJ
Pathology; 2015 Jun; 47(4):302-7. PubMed ID: 25938359
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemistry of cytokeratins 7, 8, 17, 18, and 19, and GLUT-1 aids differentiation of desmoplastic malignant mesothelioma from fibrous pleuritis.
Horiuchi T; Ogata S; Tominaga S; Hiroi S; Kawahara K; Hebisawa A; Irei I; Ito I; Kameya T; Tsujimura T; Nakano T; Nakanishi K; Kawai T
Histol Histopathol; 2013 May; 28(5):663-70. PubMed ID: 23224745
[TBL] [Abstract][Full Text] [Related]
32. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
[TBL] [Abstract][Full Text] [Related]
33. The established and future biomarkers of malignant pleural mesothelioma.
Panou V; Vyberg M; Weinreich UM; Meristoudis C; Falkmer UG; Røe OD
Cancer Treat Rev; 2015 Jun; 41(6):486-95. PubMed ID: 25979846
[TBL] [Abstract][Full Text] [Related]
34. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis.
Takeda M; Kasai T; Enomoto Y; Takano M; Morita K; Kadota E; Nonomura A
Pathol Int; 2010 May; 60(5):395-9. PubMed ID: 20518890
[TBL] [Abstract][Full Text] [Related]
35. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
[TBL] [Abstract][Full Text] [Related]
36. Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.
Sacco JJ; Kenyani J; Butt Z; Carter R; Chew HY; Cheeseman LP; Darling S; Denny M; Urbé S; Clague MJ; Coulson JM
Oncotarget; 2015 May; 6(15):13757-71. PubMed ID: 25970771
[TBL] [Abstract][Full Text] [Related]
37. Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.
Matsumoto S; Nabeshima K; Hamasaki M; Shibuta T; Umemura T
Med Oncol; 2014 Dec; 31(12):303. PubMed ID: 25358615
[TBL] [Abstract][Full Text] [Related]
38. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
Lo Iacono M; Monica V; Righi L; Grosso F; Libener R; Vatrano S; Bironzo P; Novello S; Musmeci L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2015 Mar; 10(3):492-9. PubMed ID: 25514803
[TBL] [Abstract][Full Text] [Related]
39. Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review.
Hashimoto K; Okuma Y; Hosomi Y; Hishima T
BMC Cancer; 2016 Sep; 16(1):718. PubMed ID: 27599565
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
Alì G; Borrelli N; Riccardo G; Proietti A; Pelliccioni S; Niccoli C; Boldrini L; Lucchi M; Mussi A; Fontanini G
J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
